Compare · AZN vs CPRX
AZN vs CPRX
Side-by-side comparison of AstraZeneca PLC (AZN) and Catalyst Pharmaceuticals Inc. (CPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and CPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 67.9x CPRX ($3.85B).
- Over the past year, AZN is down 10.3% and CPRX is up 49.6% - CPRX leads by 60.0 points.
- CPRX has been more active in the news (42 items in the past 4 weeks vs 15 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 7 for CPRX).
- Company
- AstraZeneca PLC
- Catalyst Pharmaceuticals Inc.
- Price
- $168.85-0.24%
- $31.49+0.03%
- Market cap
- $261.92B
- $3.85B
- 1M return
- -5.56%
- +0.41%
- 1Y return
- -10.32%
- +49.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2006
- News (4w)
- 15
- 42
- Recent ratings
- 25
- 7
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest CPRX
- Chief HR Officer Russo Gregg returned $14,994 worth of shares to the company (476 units at $31.50), closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Legal Officer Elsbernd Brian returned $7,638,782 worth of shares to the company (242,501 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Director Curran Daniel J. to cover taxes
- Director Thompson Tamar returned $118,850 worth of shares to the company (3,773 units at $31.50), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Chief Op. & Scientific Officer Miller Steve returned $34,454,794 worth of shares to the company (1,093,803 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Tierney David S returned $12,074,391 worth of shares to the company (383,314 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Strategy Officer Sundaram Preethi returned $1,726,326 worth of shares to the company (54,804 units at $31.50), closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Chairman of Board of Directors Mcenany Patrick J returned $131,404,108 worth of shares to the company (4,171,559 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President and CEO Daly Richard J returned $8,544,879 worth of shares to the company (271,266 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Del Carmen Jeffrey returned $451,616 worth of shares to the company (14,337 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)